Utilizing RNA interference to enhance cancer drug discovery

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature reviews. Drug discovery

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd2355PMID 17599085
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Why is cancer drug discovery so difficult?

  2007cited by this paper
• Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells

  2007cited by this paper
• Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies

  2007cited by this paper
• Mediators of vascular remodelling co-opted for sequential steps in lung metastasis

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Synthetic lethal screen identification of chemosensitizer loci in cancer cells

  2007cited by this paper
• Chemical genetics: where genetics and pharmacology meet.

  2007cited by this paper
• High-Throughput Screening by RNA Interference: Control of Two Distinct Types of Variance

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.

  2006cited by this paper
• A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling

  2006cited by this paper
• A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

  2006cited by this paper
• Minimizing the risk of reporting false positives in large-scale RNAi screens

  2006cited by this paper
• Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells

  2006cited by this paper
• Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.

  2006cited by this paper
• A loss-of-function RNA interference screen for molecular targets in cancer

  2006cited by this paper
• Inhibition of Viruses by RNA Interference

  2006cited by this paper
• Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin

  2006cited by this paper
• The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

  2006cited by this paper
• Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Microarrays of lentiviruses for gene function screens in immortalized and primary cells

  2006cited by this paper
• On the origin and functions of RNA-mediated silencing: from protists to man

  2006cited by this paper
• Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance

  2006cited by this paper
• RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

  2006cited by this paper
• An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

  2006cited by this paper
• In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes

  2006cited by this paper
• Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

  2006cited by this paper
• Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target

  2006cited by this paper
• RNA interference: mechanisms of action and therapeutic consideration.

  2006cited by this paper
• New approaches to molecular cancer therapeutics

  2006cited by this paper
• 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets

  2006cited by this paper
• Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.

  2005cited by this paper
• A genetic screen for candidate tumor suppressors identifies REST.

  2005cited by this paper
• A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.

  2005cited by this paper
• Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Pol II–Expressed shRNA Knocks Down Sod2 Gene Expression and Causes Phenotypes of the Gene Knockout in Mice

  2005cited by this paper
• Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance

  2005cited by this paper
• A resource for large-scale RNA-interference-based screens in mammals

  2004cited by this paper
• The Knockout Mouse Project

  2004cited by this paper
• RNA interference microarrays: high-throughput loss-of-function genetics in mammalian cells.

  2004cited by this paper
• Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

  2004cited by this paper
• An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division

  2004cited by this paper
• Genome-Wide RNAi Analysis of Growth and Viability in Drosophila Cells

  2004cited by this paper
• A large-scale RNAi screen in human cells identifies new components of the p53 pathway

  2004cited by this paper
• Parallel Chemical Genetic and Genome-Wide RNAi Screens Identify Cytokinesis Inhibitors and Targets

  2004cited by this paper
• Mechanisms of gene silencing by double-stranded RNA

  2004cited by this paper
• An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

  2003cited by this paper
• Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference.

  2003cited by this paper
• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

  2003cited by this paper
• Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

  2003cited by this paper
• Transgenic RNA interference in ES cell–derived embryos recapitulates a genetic null phenotype

  2003cited by this paper
• siRNAs can function as miRNAs

  2003cited by this paper
• siRNAs can function as miRNAs.

  2003cited by this paper
• Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.

  2002cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells

  2002cited by this paper
• A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

  2002cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Use of isogenic human cancer cells for high-throughput screening and drug discovery

  2001cited by this paper
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

  1999cited by this paper
• Targeted mRNA degradation by double-stranded RNA in vitro.

  1999cited by this paper
• Integrating genetic approaches into the discovery of anticancer drugs.

  1997cited by this paper
• Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans.

  1990cited by this paper

• RNA Delivery Using a Graphene Oxide-Polyethylenimine Hybrid Inhibiting Myotube Differentiation

  2025cites this paper
• Investigation the immunotherapeutic potential of miR-4477a targeting PD-1/PD-L1 in breast cancer cell line using a CD8+ co-culture model

  2025cites this paper
• The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

  2025cites this paper
• Structural stability-aware deep learning: advancing RNA secondary structure prediction

  2024cites this paper
• Small interference (RNAi) technique: Exploring its clinical applications, benefits and limitations

  2023cites this paper
• PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune response

  2023cites this paper
• Drugs: Stages of drug development and methods to control the high usage of drugs

  2023cites this paper
• RFold: RNA Secondary Structure Prediction with Decoupled Optimization

  2023cites this paper
• miR-92a-3p regulates cisplatin-induced cancer cell death

  2023cites this paper
• Caenorhabditis elegans as a Valuable Model for Studying Apoptosis and Autophagy in Cancer Development: Current insights, Future directions, and Challenges

  2022cites this paper
• Dynamic covalent macrocycles co-delivering genes and drugs against drug-resistant cancer

  2022cites this paper
• RFold: Towards Simple yet Effective RNA Secondary Structure Prediction

  2022cites this paper
• Nanoflare Couple: Multiplexed mRNA Imaging and Logic-Controlled Combinational Therapy.

  2022cites this paper
• Deciphering RNA Secondary Structure Prediction: A Probabilistic K-Rook Matching Perspective

  2022cites this paper
• Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies

  2022cites this paper
• Natural products targeting cancer cell dependency

  2021cites this paper
• Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

  2021cites this paper
• Non-Pigmented Ciliary Epithelium-Derived Extracellular Vesicles Loaded with SMAD7 siRNA Attenuate Wnt Signaling in Trabecular Meshwork Cells In Vitro

  2021cites this paper
• Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity

  2021cites this paper
• The importance of co‐delivery of nanoparticle‐siRNA and anticancer agents in cancer therapy

  2021cites this paper
• High-throughput synthetic rescue for exhaustive characterization of suppressor mutations in human genes

  2020cites this paper
• Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing.

  2020cites this paper
• RNA Secondary Structure Prediction By Learning Unrolled Algorithms

  2020cites this paper
• FAMSi: A Synthetic Biology Approach to the Fast Assembly of Multiplex siRNAs for Silencing Gene Expression in Mammalian Cells

  2020cites this paper
• Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease

  2020cites this paper
• Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen

  2020cites this paper
• Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways

  2019cites this paper
• Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA

  2019cites this paper
• Developing a Versatile Shotgun Cloning Strategy for Single-Vector-Based Multiplex Expression of Short Interfering RNAs (siRNAs) in Mammalian Cells

  2019cites this paper
• CRISPR Tools for Systematic Studies of RNA Regulation.

  2019cites this paper
• Bioactive Natural Products From the Genus Kalanchoe as Cancer Chemopreventive Agents: A Review

  2019cites this paper
• Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo

  2018cites this paper
• Methods and Biostatistics in Oncology

  2018cites this paper
• Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

  2018cites this paper
• Experimental Planning and Execution

  2018cites this paper
• Personalized Cancer Models for Target Discovery and Precision Medicine.

  2018cites this paper
• Characterization of the essential role of bone morphogenetic protein 9 (BMP9) in osteogenic differentiation of mesenchymal stem cells (MSCs) through RNA interference

  2018cites this paper
• A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

  2018cites this paper
• New tools for old drugs: Functional genetic screens to optimize current chemotherapy

  2018cites this paper
• Bacteriophage Fusion Peptides Based Targeted Delivery of Therapeutics to Cancer Cells

  2018cites this paper
• How to Design Phase I Trials in Oncology

  2018cites this paper
• FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer

  2018cites this paper
• Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer

  2018cites this paper
• Integration of Cell-Penetrating Peptides with Rod-like Bionanoparticles: Virus-Inspired Gene-Silencing Technology.

  2018cites this paper
• Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics

  2017cites this paper
• ‘Big data’ approaches for novel anti-cancer drug discovery

  2017cites this paper
• Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.

  2017cites this paper
• Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcription

  2017cites this paper
• Logic Modeling in Quantitative Systems Pharmacology

  2017cites this paper
• Molecular Mechanisms and Biological Functions of siRNA

  2017cites this paper
• Integrating Heterogeneous Datasets for Cancer Module Identification.

  2017cites this paper
• RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions

  2017cites this paper
• Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles.

  2017cites this paper
• Identification and Characterization of Potential Novel Targets in Thyroid Carcinoma: Evidence of Non-Oncogene Addiction Unveiling Tumor Cell Vulnerabilities

  2017cites this paper
• Identification of regulators of mutant p53 accumulationin lymphoma using RNA interference

  2017cites this paper
• Approaches to modernize the combination drug development paradigm

  2016cites this paper
• siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.

  2016cites this paper
• Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models.

  2016cites this paper
• Trial watch – inhibiting PARP enzymes for anticancer therapy

  2016cites this paper
• Current attempts to implement siRNA-based RNAi in leukemia models.

  2016cites this paper
• Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis

  2016cites this paper
• Data driven approaches to identify determinants of heart diseases and cancer resistance

  2016cites this paper
• Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery.

  2016cites this paper
• Data Analysis for High-Throughput RNAi Screening.

  2016cites this paper
• Recent Advances in Chitosan-Based Gene Carrier Application and Design

  2016cites this paper
• Creation Of Novel Inducible Cell Line To Study Alveolar Rhabdomyosarcoma

  2016influential citation
• Human Pluripotent Stem Cell‐Derived Cardiomyocytes

  2016cites this paper
• Delivery of siRNA targeting tumor metabolism using non-covalent PEGylated chitosan nanoparticles: Identification of an optimal combination of ligand structure, linker and grafting method.

  2016cites this paper
• Delivery strategies and potential targets for siRNA in major cancer types.

  2016cites this paper
• Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells

  2016cites this paper
• Systems biology approaches for advancing the discovery of effective drug combinations

  2015cites this paper
• Acoustic Liquid Handling for Rapid siRNA Transfection Optimization

  2015cites this paper
• Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells

  2015cites this paper
• Downregulation of Kinesin Spindle Protein Inhibits Proliferation, Induces Apoptosis and Increases Chemosensitivity in Hepatocellular Carcinoma Cells

  2015cites this paper
• Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

  2015cites this paper
• Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia.

  2015cites this paper
• Genome-Wide Screening of Genes Required for Glycosylphosphatidylinositol Biosynthesis

  2015cites this paper
• Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.

  2014cites this paper
• Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells

  2014cites this paper
• Remote-controlled release of DNA in living cells via simultaneous light and host-guest mediations.

  2014cites this paper
• Applications of RNA interference high-throughput screening technology in cancer biology and virology

  2014cites this paper
• A Simplified and Versatile System for the Simultaneous Expression of Multiple siRNAs in Mammalian Cells Using Gibson DNA Assembly

  2014cites this paper
• Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.

  2014cites this paper
• Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability.

  2014cites this paper
• Reversing Multidrug-Resistant by RNA Interference Through Silencing MDR1 Gene in Human Hepatocellular Carcinoma Cells Subline Bel-7402/ADM

  2014cites this paper
• Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells

  2014cites this paper
• Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.

  2014cites this paper
• Potential of siRNA Therapy in Chronic Myeloid Leukemia

  2014cites this paper
• Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.

  2014cites this paper
• Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy

  2014cites this paper
• Intracellular Delivery II

  2014cites this paper
• Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

  2014cites this paper
• Anticancer use of nanoparticles as nucleic acid carriers.

  2014cites this paper
• Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?

  2014cites this paper
• Specific Modulation of Protein Activity by Using a Bioorthogonal Reaction

  2014cites this paper
• Unraveling the DNA Damage Response Signaling Network Through RNA Interference Screening

  2014cites this paper
• Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.

  2013cites this paper
• Establishment of human lymphoma cell lines with different thiopurine S-methyltransferase (TPMT) activities and differential proteome analysis after thiopurine exposure.

  2013cites this paper
• Analyzing the Structure, Function and Information Flow in Signaling Networks using Quantitative Cellular Signatures

  2013cites this paper
• Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

  2013cites this paper